Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin for Non-muscle-invasive Bladder Cancer
NCT03379909Phase 2Recruiting
- Sponsor
- University of Amsterdam
- Start
- Sep 2019
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of liquid metformin (Aspargo Labs) in non-muscle-invasive bladder cancer (NMIBC), sponsored by University of Amsterdam. Started Sep 2019; status: recruiting.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT03379909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03379909.